News

This Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher disease (PMD). Currently, there are no approved

The randomized, double-blind, placebo-controlled, single-center, single ascending dose study is expected to evaluate the safety and pharmacokinetic profile of SPL-017. A total of 74 healthy adult male subjects are expected to be

As part of the restructuring and to further reduce costs, chief development officer, Pierre Etienne; chief commercial officer, Mona Haynes; and, vice president of operations and head of

Beacon has said that the new business relates to the implementation of its recently announced I(3)MAC (innovative, intelligent, installation, move, add, change) infrastructure management platform. Bruce Widener, CEO

The cases were filed by Orthopedic Development Corporation (ODC) and minSURG against NuFix, Nutech and their principals, and involve various claims, including ODC’s claims of infringement of its

In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the brief visuospatial memory

Under the terms of the agreement, Pfizer will receive exclusive rights to commercialize Xiaflex in the 27 member countries of the EU and 19 other European and Eurasian

Study 206 is a double-blind, placebo-controlled, dose range finding, multi- center European Phase IIb trial in about 300 migraineurs who suffer from three or more migraine attacks per

In addition to the closing purchase price, Isis will receive earn out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits. Abbott